Novartis says court battle will delay its Enbrel copy until 2018 at least

The Novartis copy of Amgen's blockbuster psoriasis drug Enbrel will not go on sale before 2018 at the earliest because of the U.S. company's patent protection challenge, the Swiss drugmaker's head of generics told Reuters. Richard Francis, head of Novartis's Sandoz generics business, said it will be at least another year before the legal fight plays out.